Redeye's first comment on Nanologica's fourth-quarter report. The company reported the strongest sales number for a single quarter so far and thus beat our expectations. The drug delivery area was the main driver behind the healthy development. Costs were also lower than we expected and the operating profit, therefore, better than expected. We will return with an update.